Literature DB >> 11309683

Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews.

R Durst1, R Colombo, S Shpitzen, L B Avi, Y Friedlander, R Wexler, F J Raal, D A Marais, J C Defesche, M Y Mandelshtam, M J Kotze, E Leitersdorf, V Meiner.   

Abstract

G197del is the most prevalent LDL receptor (LDLR) mutation causing familial hypercholesterolemia (FH) in Ashkenazi Jew (AJ) individuals. The purpose of this study was to determine the origin, age, and population distribution of G197del, as well as to explore environmental and genetic effects on disease expression. Index cases from Israel (n=46), South Africa (n=24), Russia (n=7), The Netherlands (n=1), and the United States (n=1) were enlisted. All trace their ancestry to Lithuania. A highly conserved haplotype (D19S221:104-D19S865:208-D19S413:74) was identified in G197del chromosomes, suggesting the occurrence of a common founder. When two methods were used for analysis of linkage disequilibrium (LD) between flanking polymorphic markers and the disease locus and for the study of the decay of LD over time, the estimated age of the deletion was found to be 20 +/- 7 generations (the 95% confidence interval is 15-26 generations), so that the most recent common ancestor of the mutation-bearing chromosomes would date to the 14th century. This corresponds with the founding of the Jewish community of Lithuania (1338 a.d.), as well as with the great demographic expansion of AJ individuals in eastern Europe, which followed this settlement. The penetrance of mutation-linked severe hypercholesterolemia is high (94% of heterozygotes have a baseline concentration of LDL cholesterol (LDL-C) that is >160 mg/dl), and no significant differences in the mean baseline lipid level of G197del carriers from different countries were found. Polymorphisms of apolipoprotein E and of scavenger-receptor class B type I were observed to have minor effects on the plasma lipid profile. With respect to determinative genetic influences on the biochemical phenotype, there is no evidence that could support the possibility of a selective evolutionary metabolic advantage. Therefore, the founder effect in a rapidly expanding population from a limited number of families remains a simple, parsimonious hypothesis explaining the spread of G197del-LDLR-linked FH in AJ individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309683      PMCID: PMC1226098          DOI: 10.1086/320123

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  68 in total

1.  The mutation rate in the human mtDNA control region.

Authors:  S Sigurğardóttir; A Helgason; J R Gulcher; K Stefansson; P Donnelly
Journal:  Am J Hum Genet       Date:  2000-04-07       Impact factor: 11.025

2.  Estimating the age of mutant disease alleles based on linkage disequilibrium.

Authors:  S W Guo; M Xiong
Journal:  Hum Hered       Date:  1997 Nov-Dec       Impact factor: 0.444

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  ITD in Ashkenazi Jews--genetic drift or selection?

Authors:  A Zoossmann-Diskin
Journal:  Nat Genet       Date:  1995-09       Impact factor: 38.330

5.  Mutation of human short tandem repeats.

Authors:  J L Weber; C Wong
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

6.  Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.

Authors:  S Bertolini; A Cantafora; M Averna; C Cortese; C Motti; S Martini; G Pes; A Postiglione; C Stefanutti; I Blotta; L Pisciotta; M Rolleri; S Langheim; M Ghisellini; I Rabbone; S Calandra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-09       Impact factor: 8.311

7.  Age estimate of the N370S mutation causing Gaucher disease in Ashkenazi Jews and European populations: A reappraisal of haplotype data.

Authors:  R Colombo
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

Review 8.  APO E gene and gene-environment effects on plasma lipoprotein-lipid levels.

Authors:  J M Hagberg; K R Wilund; R E Ferrell
Journal:  Physiol Genomics       Date:  2000-12-18       Impact factor: 3.107

9.  Homozygous familial hypercholesterolemia among French Canadians in Québec Province.

Authors:  S Moorjani; M Roy; C Gagné; J Davignon; D Brun; M Toussaint; M Lambert; L Campeau; S Blaichman; P Lupien
Journal:  Arteriosclerosis       Date:  1989 Mar-Apr

10.  Familial hypercholesterolemia and apolipoprotein E4.

Authors:  M Eto; K Watanabe; N Chonan; K Ishii
Journal:  Atherosclerosis       Date:  1988-08       Impact factor: 5.162

View more
  12 in total

1.  Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection.

Authors:  Neil Risch; Hua Tang; Howard Katzenstein; Josef Ekstein
Journal:  Am J Hum Genet       Date:  2003-02-24       Impact factor: 11.025

2.  A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases.

Authors:  Montgomery Slatkin
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

3.  Familial hypercholesterolaemia.

Authors:  A David Marais
Journal:  Clin Biochem Rev       Date:  2004-02

4.  The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia.

Authors:  Alexey Meshkov; Alexandra Ershova; Anna Kiseleva; Evgenia Zotova; Evgeniia Sotnikova; Anna Petukhova; Anastasia Zharikova; Pavel Malyshev; Tatyana Rozhkova; Anastasia Blokhina; Alena Limonova; Vasily Ramensky; Mikhail Divashuk; Zukhra Khasanova; Anna Bukaeva; Olga Kurilova; Olga Skirko; Maria Pokrovskaya; Valeriya Mikova; Ekaterina Snigir; Alexsandra Akinshina; Sergey Mitrofanov; Daria Kashtanova; Valentin Makarov; Valeriy Kukharchuk; Sergey Boytsov; Sergey Yudin; Oxana Drapkina
Journal:  Genes (Basel)       Date:  2021-01-06       Impact factor: 4.096

5.  Tay-Sachs disease preconception screening in Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state better than does ancestral origin, although there is an increased risk for c.1421 + 1G > C mutation in individuals with South African heritage.

Authors:  Raelia Lew; Leslie Burnett; Anné Proos
Journal:  J Community Genet       Date:  2011-07-15

6.  Haplotype analyses, mechanism and evolution of common double mutants in the human LDL receptor gene.

Authors:  M T Tejedor; A Cenarro; D Tejedor; M Stef; R Mateo-Gallego; I de Castro; A L García-Otin; L V Monteagudo; F Civeira; M Pocovi
Journal:  Mol Genet Genomics       Date:  2010-04-29       Impact factor: 3.291

Review 7.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

8.  Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a robust and parsimonious hypothesis.

Authors:  Amos Frisch; Roberto Colombo; Elena Michaelovsky; Mazal Karpati; Boleslaw Goldman; Leah Peleg
Journal:  Hum Genet       Date:  2004-01-15       Impact factor: 4.132

9.  A population-based study of autosomal-recessive disease-causing mutations in a founder population.

Authors:  Jessica X Chong; Rebecca Ouwenga; Rebecca L Anderson; Darrel J Waggoner; Carole Ober
Journal:  Am J Hum Genet       Date:  2012-09-13       Impact factor: 11.025

10.  Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor.

Authors:  Mazal Karpati; Ephraim Gazit; Boleslaw Goldman; Amos Frisch; Roberto Colombo; Leah Peleg
Journal:  Neurogenetics       Date:  2003-11-27       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.